Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer — 126ASC08Q

Advanced Solid Cancers Clinical Trial

Official title:
Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics of Docetaxel Between Two Docetaxel Products, CKD-810 and Taxotere Inj., in Patients With Advanced Solid Cancer

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate safety and the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer.

Clinical Trial Description

This is a Phase III study designed to evaluate the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer. This study will also assess the safety of the docetaxel in advanced solid cancer patients. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced Solid Cancers

Clinical Trial Details

NCT number	NCT01019941
Study type	Interventional
Source	Chong Kun Dang Pharmaceutical
Contact
Status	Completed
Phase	Phase 1
Start date	August 2009
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02792465` - A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT00886782` - A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT03956680` - An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers	Phase 1
Completed	`NCT03512340` - Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers	Phase 1
Terminated	`NCT03254732` - Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers	Phase 1
Completed	`NCT00478101` - Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain	Phase 2
Terminated	`NCT00337376` - A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers	Phase 1
Completed	`NCT02694822` - AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy	Phase 1/Phase 2